Cyclopharm Limited provided sales guidance for the half year ended 30 June 2022. The company expected revenue is expected to be approximately $11.3 million, 36% higher than pcp and 74% higher than the company's pre-COVID revenues in first half 2019.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.42 AUD | -1.05% | -13.94% | -26.23% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-26.23% | 101M | |
+6.54% | 217B | |
+12.23% | 190B | |
+19.19% | 143B | |
+30.41% | 111B | |
+0.65% | 64.59B | |
+15.19% | 52.36B | |
+2.06% | 48.45B | |
-5.65% | 38.03B | |
-0.19% | 35.6B |
- Stock Market
- Equities
- CYC Stock
- News Cyclopharm Limited
- Cyclopharm Limited Provides Sales Guidance for the Half Year Ended 30 June 2022